Company / Accounts Receivable
NovaBay Pharmaceuticals, Inc. Accounts Receivable History
FY2022-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$759.0K
FY2023
5-year range
$759.0K / $2.0M
FY2022-FY2023
Trend
-61.5%
vs FY2022
Sector context
#107 of 115
Health Care
What the data says
Among 115 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the bottom 7% for accounts receivable.
Based on SEC 10-K filings.
$759,000 in FY2023.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 115This company $759.0K Sector average $1.1B
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2023, accounts receivable decreased 61.5% year-over-year.
- Ranks #107 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $759.0K | -61.5% |
| FY2022 | $2.0M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | - | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026